Compugen (CGEN) Stock: Buy, Sell, or Hold?
CGEN - Compugen Ltd
$1.96
-0.16 (-7.55%)
âŧ
5d:
-5.77%
30d:
-16.24%
90d:
-14.04%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 09, 2026
16d
Get Alerted When CGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CGEN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CGEN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CGEN is currently trading at $1.96, which is considered slightly low relative to its 30-day fair value range of $2.10 to $2.44.
Technical Outlook: Technically, CGEN is showing sideways momentum. The price is currently testing key support at $1.92. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.5% recently.
Market Sentiment: CGEN scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.60 (+134.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CGEN is showing sideways momentum. The price is currently testing key support at $1.92. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.5% recently.
Market Sentiment: CGEN scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.60 (+134.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.10 -
$2.44
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.5%)
- BULLISH: Trading 134.7% below Wall St target ($4.60)
- WARNING: Composite score 50/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.10 -
$2.44
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.92
Resistance Level
$2.20
Current Trend
Sideways
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.34
Wall Street Target
$4.60
(+134.7%)
Revenue Growth (YoY)
107.0%
Profit Margin
47.6%
Share & Embed Analysis
Last updated: October 23, 2026 7:54 AM ET
Data refreshes hourly during market hours. Next update: 8:53 AM
Data refreshes hourly during market hours. Next update: 8:53 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 39 SELL |
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 52 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 61 BUY |
|
MDGL
Madrigal PharmaceuticalsâĻ |
STRONG BUY
19 analysts |
$686 | 62 BUY |
|
PVLA
Palvella Therapeutics, IâĻ |
STRONG BUY
15 analysts |
$231 | 68 BUY |
